Pediatric studies for off-patent cancer drugs
The Pediatric Subcommittee of FDA's Oncologic Drugs Advisory Committee will consider the availability of safety and efficacy data on off-patent oncology drugs for the pediatric population and whether additional information is needed at an Oct. 9 meeting. Age-appropriate formulation changes to facilitate dosing of products used in the pediatric oncology setting will also be discussed. The meeting will be held at the Holiday Inn in Silver Spring, Md. beginning at 8 a.m...
You may also be interested in...
Early results from its novel antiviral are encouraging, but demonstrating life-saving qualities in a short window of time will be tricky.
After federal agencies invested almost $5600m to ensure Cue Health could scale up production, FDA announces the self-administered test will be available OTC. it's the agency's first emergency use authorization for an at-home molecular diagnostic test available nonprescription.
Tezepelumab was among four products that the European Medicines Agency most recently considered for review under its accelerated assessment mechanism.